Theravance and GSK launch Breo Ellipta in USA

30 October 2013

UK pharma major GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX) today announced that Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for chronic obstructive pulmonary disease (COPD) is available to US pharmacies.

Breo Ellipta was cleared for marketing earlier this year by the US Food and Drug Administration, and has been hailed as having blockbuster potential, with peak sales estimates of as much at $4 billion.

The drug is a combination of the inhaled corticosteroid (ICS) fluticasone furoate and the long-acting beta2-agonist (LABA) vilanterol, is indicated for the long-term, once‐daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. It is intended to reduce exacerbations of COPD in patients with a history of exacerbations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK